Division of Daiichi Sankyo Co. Ltd.
Latest From Plexxikon Inc.
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
As part of its strategic pivot towards oncology, Daiichi Sankyo reaches a global out-licensing deal with a little-known US venture for an early-stage asset, which also hints at where its priorities lie.
Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
K. Peter Hirth, PhD, CEO
Kathleen Sereda Glaub, Pres.
Gideon E Bollag, PhD, SVP, Research
- Contact Info
Phone: (510) 647-4000
91 Bolivar Dr.
Berkeley, CA 94710
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.